Sulodexide and Alzheimer’s Disease: A Preliminary Prospective Study
| Autor: | María Mercedes Aza Pascual-Salcedo, Joaquín Lasierra-Cirujeda, María José Aza Pascual-Salcedo |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Acenocoumarol
medicine.medical_specialty business.industry Disease 030204 cardiovascular system & hematology Sulodexide Surgery Pathogenesis 03 medical and health sciences 0302 clinical medicine Internal medicine Pharmacodynamics medicine In patient Prospective cohort study business Venous thromboembolism 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | World Journal of Cardiovascular Diseases. :54-71 |
| ISSN: | 2164-5337 2164-5329 |
| DOI: | 10.4236/wjcd.2016.62007 |
| Popis: | The purpose of this prospective study is to determine the relative incidence of Alzheimer’s disease in patients treated for at least three years, with sulodexide (n = 46, 76.48 ± 7.02 years old) or acenocoumarol (n = 47, 78.21 ± 6.66 years old) in order to prevent primary and secondary venous thromboembolism and atherothrombotic disease. In the sulodexide group, there was an apparent prevention of cognitive and behavioural impairment (relative incidence: 2.02) compared with acenocoumarol group (relative incidence: 4.86). The favourable results in sulodexide group may be related to their pharmacodynamic actions of inhibition of PAI-1, which may interfere with the pathogenesis of Alzheimer’s disease, and to the role of glutathione and PAI-1 in the β-amyloid system in the brain. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|